Loading…
← CockpitCompetitor Analysis › MEDI.OL Medistim ASAOpen in the cockpit ↗

Medistim ASAMEDI.OLCompetitor analysis, valuation and peers

Norway · NOK·Health Care›Medical Specialties
Momentum leader 99
Mkt cap
$599M
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$782,322
20-day average traded
Fwd P/E
31.8×
forward earnings
ROIC−WACC
+52.3 pp
WACC 5.9%
Hurdle
-16 pp
Req g minus delivered
Next earnings
100 days
26 Feb 2027
Close · NOKNOK 319.00
1D+1.3%
1W+1.9%
1M+12.3%
3M+29.7%
6M+32.4%
YTD+23.2%
1Y+35.2%
ATR %3.1%
52w lowhigh3.3% off high

What Medistim does

Employees: 159

Medistim at a glance

Size Medistim (MEDI.OL) is a Norway Health Care company (Medical Specialties) with a market value of $599M, the 77th largest of 108 Norway companies the cockpit tracks. Shares closed at NOK 319.00 on 18 Nov 2026.

Performance Over six months the shares gained 32.4%, against -20.3% for the median peer and +1.6% for the Norway market (cap-weighted) — 4th highest of 19 in its peer set.

Growth Revenue grew 19.1% over the last twelve months (peer median +14.4%); the operating margin is 28.6% (peer median 7.5%).

Valuation It trades at 31.8× forward earnings against a peer median of 20.0× (5th most expensive of 13).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 52.3 points above its cost of capital (5.9% WACC).

Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026MEDI.OL 133Peer median 81
Six months, rebased to 100: Medistim against the median of its 20 peers (local-currency closes).

Medistim financials

Reported figures in NOK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNOK 796MNOK 700MNOK 563MNOK 521MNOK 486M
Revenue growth—+24%+8%+7%—
Gross profitNOK 383MNOK 321MNOK 245MNOK 225MNOK 218M
EBITDANOK 255MNOK 219MNOK 152MNOK 150MNOK 153M
Net incomeNOK 178MNOK 159MNOK 104MNOK 104MNOK 114M
Free cash flown/aNOK 182MNOK 137MNOK 96.8MNOK 104M
Capital expendituren/aNOK 33.0MNOK 24.7MNOK 29.7MNOK 21.1M
Total debtNOK 26.2MNOK 49.3MNOK 34.4MNOK 17.6MNOK 17.1M

Quarterly statements and history in the cockpit →

Medistim competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%SGHTNANTCMD688581300314OBIOXVIVO688236300952PACB47283012356031221789300869QDELSNTMEDI.OL6-month return →1-month return →
Up and to the right = strong over both horizons. Medistim is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%50×100×NANTCMD688581300314XVIVO6882363009523012351789QDEL605369SNTMEDI.OLRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Medistim is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%NANTCMD688581XVIVO68823647281789300869605369SNTMEDI.OLGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Medistim is the large dot.

Medistim competitors and peer comparison

How Medistim compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Medistim against its 20 peers (data as of 18 Nov 2026)
MeasureMEDI.OLPeer medianRank in peer set
1-month return+12.3%-5.5%4th highest of 19
6-month return+32.4%-20.3%4th highest of 19
Distance from 52-week high-3.3%-34.3%highest of 20
Revenue growth (TTM)+19.1%+14.4%5th highest of 20
Operating margin28.6%7.5%4th highest of 20
Forward P/E31.8×20.0×5th most expensive of 13
Growth the price implies (Req g, 7 yrs)-1.2%4.4%4th least demanding of 11
Growth delivered (Del g)+14.5%+9.3%5th highest of 11
Hurdle (Req g minus delivered)-15.6 pp-7.2 pp5th least demanding of 11
ROIC minus cost of capital+52.3 pp+0.1 pp3rd highest of 19
EV / EBITDA22.2×13.2×3rd most expensive of 8
Net debt / EBITDA-0.6×-1.0×3rd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Medistim MEDI.OLNorway$599M+32%+19%29%31.8×-1.2%+14.5%
Sight Sciences SGHTUnited States$599M+122%+16%-30%n/an/an/a
Nanosonics NAN.AXAustralia$599M-4%+3%7%98.6×35.3%+6.7%
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
vVARDIS VVVVUnited States$594Mn/a+148%-72%n/an/an/a
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%21.1×8.4%+12.0%
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%18.9×0.4%+27.8%
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%12.0×n/an/a
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%n/an/an/a
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%53.1×35.9%+35.2%
Beijing Chunlizhengda Medical Instruments 688236.SSChina$618M-27%-13%31%17.4×-8.5%+2.2%
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%39.7×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%n/an/an/a
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%n/a-2.6%+18.8%
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%33.7×n/an/a
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%n/an/an/a
AK Medical 1789.HKHong Kong$642M-23%+16%26%10.5×-11.5%+6.7%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%n/a15.0%-19.8%
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%23.5×10.2%+6.5%
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%

Questions

Which companies are Medistim's closest peers?
The cockpit's peer set: Sight Sciences (SGHT), Nanosonics (NAN.AX), Sahajanand Medical Technologies (SMT.NS), vVARDIS (VVVV), Tactile Systems Technology (TCMD), Hangzhou AGS MedTech (688581.SS), Ningbo David Medical Device (300314.SZ), Orchestra BioMed (OBIO).
Is Medistim expensive compared with its peers?
On forward p/e it trades at 31.8× against a peer median of 20.0×, 5th most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -16 pp: the price already allows for a slowdown.
How has Medistim stock performed?
Over six months to 18 Nov 2026 the shares returned +32.4% against -20.3% for the median peer; over one year +35.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.